Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Receivables (2018 - 2025)

10x Genomics' Receivables history spans 8 years, with the latest figure at $82.5 million for Q4 2025.

  • For Q4 2025, Receivables fell 6.75% year-over-year to $82.5 million; the TTM value through Dec 2025 reached $82.5 million, down 6.75%, while the annual FY2025 figure was $82.5 million, 6.75% down from the prior year.
  • Receivables for Q4 2025 was $82.5 million at 10x Genomics, down from $96.6 million in the prior quarter.
  • Across five years, Receivables topped out at $119.1 million in Q2 2025 and bottomed at $52.5 million in Q1 2025.
  • The 5-year median for Receivables is $84.4 million (2021), against an average of $85.5 million.
  • The largest annual shift saw Receivables soared 162.61% in 2021 before it crashed 42.45% in 2025.
  • A 5-year view of Receivables shows it stood at $85.3 million in 2021, then rose by 22.24% to $104.2 million in 2022, then rose by 10.19% to $114.8 million in 2023, then dropped by 22.96% to $88.5 million in 2024, then fell by 6.75% to $82.5 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Receivables are $82.5 million (Q4 2025), $96.6 million (Q3 2025), and $119.1 million (Q2 2025).